Projects

Finding alternatives for conventional multiple injection vaccines
Vaccination is generally considered to be the most effective and cost-effective method of preventing infectious diseases. However, poor patient compliance, inadequate delivery and lack of efficiency are limiting factors in vaccination programs.

This project aims to develop alternative, preferably needleless methods of vaccine delivery. The development strategy is based on nano- and microparticles for vaccinations through the nose and skin. Apparent is that the efficiency of a vaccine increases as the size of its particles decreases. Surprisingly the researchers have found the perfect vessel for the vaccine in lobster shells. Adding nanoscopic particles of these shells increases the effectiveness of nasal vaccines dramatically, overcoming bottlenecks such as bioavailability and effectiveness of vaccines. The results from this project may lead to new and improved vaccination strategies that can be used for the prevention or treatment of infectious diseases, cancer, and autoimmune diseases.

Fast facts
Full project title: Vaccine delivery: alternatives for conventional multiple injection vaccines
Start date: September 2006
End date: September 2011
Goal: Design new improved vaccine delivery methods
Contact: Wim Jiskoot
Project size: 4,5 FTE
Background: Vaccination
Partners: Leiden University, Netherlands Vaccine Institute, OctoPlus NV, Utrecht University, VU University Medical Center Amsterdam

Background

Vaccination programs are aimed at generating immunity against a diseases. Commonly, a weakened or killed pathogen, such as bacteria or a virus, is administered using an injection. The administered pathogen isn’t strong enough to be dangerous and cause severe illness, but does trigger the host’s immune system. Because our adaptive immune system ‘records’ the pathogen and the proper defense against it, the system is able to fight off that specific full-force pathogen, in case of future infection. 

Vaccination is considered the most effective and cost-effective method to prevent infectious diseases.

PhD theses from this project

Chantal Keijzer (project D5-106)
Nanoparticles for Nasal Delivery of Vaccines

“One of TI Pharma's big strengths is that it knows how to manage money. That's a skill that should be more widespread.”

Tim Wells
Chief Scientific Officer
Medicines for Malaria Venture

Share this page: